Clinical trial
Feasibility Study of Biomarker Development for Response Prediction by Large Scale DNA Mutational Analysis of Metastatic Lesions
NCT01855061 is registered in ClinicalTrials.gov with P.O. Witteveen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Feasibility Study of Biomarker Development for Response Prediction by Large Scale DNA Mutational Analysis of Metastatic Lesions
- Lead sponsor
- P.O. Witteveen
- Phase
- Observational
- Overall status
- Terminated
- Start date
- May 31, 2011
- Completion date
- August 31, 2016
- Enrollment
- 79 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.